NCT02004522 · OUTCOME

Number of Subjects With Samples Available for Duvelisib Pharmacokinetics (PK)

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) · Source last updated 2023-09-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Number of subjects with samples available for duvelisib Pharmacokinetics (PK)

Analysis population: Intent to Treat for duvelisib patients, no PK samples were collected for ofatumumab patients.

Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Duvelisib	160

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Duvelisib	158	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Number of subjects with samples available for duvelisib Pharmacokinetics (PK)

groups

param Type

NUMBER

population Description

Intent to Treat for duvelisib patients, no PK samples were collected for ofatumumab patients.

reporting Status

POSTED

time Frame

Cycle 2, Cycle 3, and Cycle 7

title

Number of Subjects With Samples Available for Duvelisib Pharmacokinetics (PK)

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice